Recent Posts

• Genascence Granted FDA Fast Track Designation for GNSC-001 in Patients with Osteoarthritis (OA) of the Knee
• Genascence Appoints Jeymi Tambiah as Chief Medical Officer
• Genascence Announces Initiation of Phase 1b Clinical Trial of GNSC-001 Gene Therapy for Knee Osteoarthritis (OA)
• Genascence to Present at Biotech Showcase 2024
• Genascence to Present Full Data from Phase 1 Clinical Trial on GNSC-001, Company’s Lead Program in Osteoarthritis, at European Society of Gene & Cell Therapy 30 th Annual Congress